Bellevue Group Ag Cellectis S.A. Transaction History

Bellevue Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$3.45 - $8.77 $284,625 - $723,525	-82,500 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$11.94 - $16.09 $11,940 - $16,090	-1,000 Reduced 1.2%	82,500 $1.04 Million
Q2 2020 Aug 13, 2020	BUY	$8.21 - $21.02 $67,322 - $172,364	8,200 Added 10.89%	83,500 $1.49 Million
Q1 2020 May 14, 2020	BUY	$7.81 - $18.82 $588,093 - $1.42 Million	75,300 New	75,300 $693,000
Q1 2019 May 15, 2019	SELL	$15.53 - $19.75 $726,027 - $923,312	-46,750 Closed	0 $0
Q4 2018 Feb 12, 2019	SELL	$15.58 - $28.41 $44,403 - $80,968	-2,850 Reduced 5.75%	46,750 $778,000
Q3 2018 Nov 13, 2018	SELL	$25.99 - $30.6 $25,990 - $30,600	-1,000 Reduced 1.98%	49,600 $1.4 Million
Q2 2018 Aug 07, 2018	SELL	$27.78 - $38.53 $41,670 - $57,795	-1,500 Reduced 2.88%	50,600 $1.43 Million
Q1 2018 May 09, 2018	BUY	$27.78 - $35.19 $770,895 - $976,522	27,750 Added 113.96%	52,100 $1.64 Million
Q4 2017 Feb 14, 2018	BUY	$23.33 - $35.01 $568,085 - $852,493	24,350	24,350 $710,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $91.9M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.